Sustained-release product comprising a combination of a non-opioid amine and a non-steriodal anti-inflammatory drug
AssigneeUpsher-Smith Laboratories, Inc.
InventorsChristian F. Wertz, James S. Jensen, Victoria Ann O'Neill, Sean B. Mahoney, Stephen M. Berge
Life of this patent
Estimating the term…
Abstract
Sustained-release oral pharmaceutical compositions and methods of use, wherein the compositions are in a single dosage form and include an amine-containing compound (including salts thereof), a salt of a non-steroidal anti-inflammatory drug (NSAID), and a hydrophilic matrix.
Claims19
A sustained-release oral pharmaceutical composition comprising within a single dosage form:
- a hydrophilic matrix;
- a therapeutically effective amount of a non-opioid amine-containing compound;
- and
- a salt of a non-steroidal anti-inflammatory drug (NSAID);
- wherein the amine-containing compound and the salt of an NSAID are within the hydrophilic matrix;
- and
- wherein the composition exhibits a release profile of the amine-containing compound comprising a substantial portion that is representative of zero-order release kinetics under in vitro conditions.
A sustained-release oral pharmaceutical composition comprising within a single dosage faun:
- a hydrophilic matrix;
- a therapeutically effective amount of a non-opioid amine-containing compound;
- a salt of a non-steroidal anti-inflammatory drug (NSAID);
- and
- a pharmaceutically acceptable anionic surfactant;
- wherein the amine-containing compound, the salt of an NSAID, and the anionic surfactant are within the hydrophilic matrix.
A sustained-release oral pharmaceutical composition comprising within a single dosage form:
- a hydrophilic matrix;
- a therapeutically effective amount of an amine-containing compound selected from the group consisting of dextromethorphan, cyclobenzaprine, benztropine, ritodrine, memantine, amantadine, salts thereof, and combinations thereof;
- and
- a salt of a non-steroidal anti-inflammatory drug (NSAID) selected from the group consisting of a salt of naproxen, diclofenac, ibuprofen, and combinations thereof;
- wherein the amine-containing compound and the salt of an NSAID are within the hydrophilic matrix;
- and
- wherein the composition exhibits a release profile of the amine-containing compound comprising a substantial portion that is representative of zero-order release kinetics under in vitro conditions.
A sustained-release oral pharmaceutical composition comprising within a single dosage form:
- a hydrophilic matrix;
- a therapeutically effective amount of an amine-containing compound selected from the group consisting of dextromethorphan, cyclobenzaprine, benztropine, ritodrine, memantine, amantadine, salts thereof, and combinations thereof;
- a salt of a non-steroidal anti-inflammatory drug (NSAID) selected from the group consisting of a salt of naproxen, diclofenac, ibuprofen, and combinations thereof;
- and
- a pharmaceutically acceptable anionic surfactant selected from the group consisting of sodium lauryl sulfate, docusate sodium, docusate calcium, and combinations thereof;
- wherein the amine-containing compound the salt of an NSAID, and the anionic surfactant are within the hydrophilic matrix.
Dependencies are inferred from the claim text.